Fibrosis, IPF and the search for better therapies

May 7, 2026 |

1 min read |

Jennifer C. Smith-Parker, BioSpace Insights

In this episode of Denatured, you’ll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder and Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung.

> Listen on Spotify
> Listen on Apple Podcasts
> Listen on Amazon Music

In this Denatured episode, Jennifer C. Smith-Parker speaks to Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder and Chief Medical Officer of Calluna Pharma. We explore the challenges of IPF and fibrosis, examining treatment barriers, emerging therapeutic targets, unmet needs and opportunities beyond pulmonary disease.

Host

⁠Jennifer C. Smith-Parker⁠, Director of Insights, BioSpace

Guests

Georg Vo Beiske, CEO, Tribune Therapeutics

Jonas Hallén, Co-Founder & CMO, Calluna Pharma

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Jennifer C. Smith-Parker

Jennifer C. Smith-Parker is Director of Insights at BioSpace. She has been been immersed for 20 years in healthcare, first as a journalist and editor before pivoting to corporate, brand, and product communications. A skilled storyteller, she is adept at creating diverse content across platforms and crafting narratives that drive engagement, strengthen reputation, and deliver measurable growth. You can reach her at Jennifer.Smith-Parker@BioSpace.com.

BioSpace Insights

The BioSpace Insights teams performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.